Exciting News: Bausch Health Expands OraPharma’s Reach to Canada and Puerto Rico!

Bausch Health Companies Inc. (NYSE:BHC) is making waves in the dental market by expanding OraPharma into Canada and Puerto Rico. This move aims to strengthen ties with dental professionals and local distributors, making it easier for patients to access treatments for periodontal disease and enhancing overall oral health awareness.

One of OraPharma’s key products, Arestin®, is notable for being FDA-approved as an antibiotic used alongside scaling and root planing (SRP) to manage periodontal disease. It helps reduce pocket depth in adults suffering from periodontitis, addressing a significant health issue.

Recent statistics reveal that 44.5% of older adults in Puerto Rico face moderate to severe periodontal disease. This stark number underscores the urgent need for better treatment options in the area. Experts stress that addressing oral health is crucial, as there’s a strong link between periodontal disease and overall health issues, including heart disease and diabetes.

Bausch Health operates several segments, including Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb, providing a broad range of pharmaceuticals and medical devices.

While BHC holds potential as an investment, many analysts believe some AI stocks might offer better returns with less risk. As the tech landscape evolves, keeping an eye on emerging trends can be beneficial. For instance, AI is reshaping many sectors, and investing in this space could lead to substantial gains.

For more insights on stocks with high growth potential, a look at recent trends and expert opinions may offer guidance on where to invest wisely.



Source link

Bausch Health Companies Inc., OraPharma, Puerto Rico, periodontal disease, Food and Drug Administration, dental professionals, Diversified Products